Home >> Healthcare Administration >> Pharmaceuticals >> Food & Beverage >>

Shigella Infections (Shigellosis) - Pipeline Review, H2 2013

Published: Dec-2013 | Format: PDF | Global Markets Direct | Number of pages: 47 | Code: MRS - 987

Global Markets Directs, 'Shigella Infections (Shigellosis) Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Shigella Infections (Shigellosis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Shigella Infections (Shigellosis). Shigella Infections (Shigellosis) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Scope

A snapshot of the global therapeutic scenario for Shigella Infections (Shigellosis).
A review of the Shigella Infections (Shigellosis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Shigella Infections (Shigellosis) pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Shigella Infections (Shigellosis).
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Shigella Infections (Shigellosis) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Shigella Infections (Shigellosis) Overview 6
Therapeutics Development 7
Pipeline Products for Shigella Infections (Shigellosis) - Overview 7
Pipeline Products for Shigella Infections (Shigellosis) - Comparative Analysis 8
Shigella Infections (Shigellosis) - Therapeutics under Development by Companies 9
Shigella Infections (Shigellosis) - Therapeutics under Investigation by Universities/Institutes 10
Shigella Infections (Shigellosis) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Shigella Infections (Shigellosis) - Products under Development by Companies 14
Shigella Infections (Shigellosis) - Products under Investigation by Universities/Institutes 15
Shigella Infections (Shigellosis) - Companies Involved in Therapeutics Development 16
GlycoVaxyn AG 16
VBI Vaccines 17
Inhibikase Therapeutics, Inc. 18
EveliQure Biotechnologies GmbH 19
Shigella Infections (Shigellosis) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Assessment by Therapeutic Class 25
Drug Profiles 27
GVXN-SD-133 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CVD-1208S Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Inactivated Whole Cell Shigella Flexneri 2a Vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
WRSs-2 Vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
WRSs-3 Vaccine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Shigetec - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Oral Shigella Vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
KKL-35 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Drug For Diarrhoea - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Shigella Infections (Shigellosis) - Recent Pipeline Updates 37
Shigella Infections (Shigellosis) - Dormant Projects 38
Shigella Infections (Shigellosis) - Product Development Milestones 39
Featured News & Press Releases 39
Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine 39
Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates 39
Oct 24, 2011: Thallion Pharmaceuticals Announces Presentation Of Blinded Results From Low Dose Cohort Of Phase II SHIGATEC Trial At IDSA Annual Meeting 41
Oct 11, 2011: Thallion Resumes Patient Recruitment In Phase II SHIGATEC Trial 41
Sep 13, 2011: Thallion Provides Update On Phase II SHIGATEC Trial 42
Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease 43
Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine 43
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 44

Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables

Number of Products under Development for Shigella Infections (Shigellosis), H2 2013 7
Number of Products under Development for Shigella Infections (Shigellosis) - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Comparative Analysis by Unknown Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
Shigella Infections (Shigellosis) - Pipeline by GlycoVaxyn AG, H2 2013 16
Shigella Infections (Shigellosis) - Pipeline by VBI Vaccines, H2 2013 17
Shigella Infections (Shigellosis) - Pipeline by Inhibikase Therapeutics, Inc., H2 2013 18
Shigella Infections (Shigellosis) - Pipeline by EveliQure Biotechnologies GmbH, H2 2013 19
Assessment by Monotherapy Products, H2 2013 20
Number of Products by Stage and Route of Administration, H2 2013 22
Number of Products by Stage and Molecule Type, H2 2013 24
Number of Products by Stage and Therapeutic Class, H2 2013 26
Shigella Infections (Shigellosis) Therapeutics - Recent Pipeline Updates, H2 2013 37
Shigella Infections (Shigellosis) - Dormant Projects, H2 2013 38 
List of Figures

Number of Products under Development for Shigella Infections (Shigellosis), H2 2013 7
Number of Products under Development for Shigella Infections (Shigellosis) - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 20
Number of Products by Top 10 Route of Administration, H2 2013 21
Number of Products by Stage and Top 10 Route of Administration, H2 2013 22
Number of Products by Top 10 Molecule Type, H2 2013 23
Number of Products by Stage and Top 10 Molecule Type, H2 2013 24
Number of Products by Top 10 Therapeutic Class, H2 2013 25
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 26

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing